Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12286464-B2
Publication Date
2025-04-29
Expiration Date
Abstract
Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Core Innovation
The invention relates to a composition that includes a caged cytokine. The caged cytokine is conjugated to a photon decomposing chemical structure, and the photon decomposing chemical structure is conjugated through a linking group to a hydrophilic polymer. The cytokine is interleukin-2, interleukin-7, interleukin-12, or interleukin-15, and the photon decomposing chemical structure has a 2-nitrobenzyl group.
In supported embodiments, the cytokine is defined using IL-2 sequence variants. Specific IL-2 variants are described as having amino-acid substitutions selected from R38A, F42A, Y45A, E61R, and L72G, and variant definitions include particular amino-acid sequences identified by SEQ ID NOs.
Additional structural embodiments specify the conjugate components and their linkage features, including defining the linker as a peptide linker made from SEQ ID NO:3 and fixing parameters associated with the linkage to the hydrophilic polymer. The disclosed framework also supports therapeutic contexts by selecting subject and disease settings, including cancers enumerated across multiple tumor types.
Claims Coverage
One independent claim is provided, covering a caged-cytokine composition with a photon-decomposing 2-nitrobenzyl group coupled via a linking group to a hydrophilic polymer, where the cytokine is selected from interleukins (IL-2, IL-7, IL-12, or IL-15). Dependent claims refine the cytokine and structural conjugate details and further constrain treatment settings by enumerating cancer types and subject contexts.
Caged cytokine composition with photon-decomposing 2-nitrobenzyl group
A composition comprising a caged cytokine wherein the caged cytokine is conjugated to a photon decomposing chemical structure, wherein the photon decomposing chemical structure has a 2-nitrobenzyl group.
Linking group to hydrophilic polymer conjugate architecture
The photon decomposing chemical structure is conjugated through a linking group to a hydrophilic polymer.
Interleukin cytokine selection as the caged cytokine
The cytokine is interleukin-2, interleukin-7, interleukin-12, or interleukin-15.
IL-2 sequence-defined embodiment
The caged cytokine is an IL-2 protein that contains the amino acid sequence of SEQ ID NO: 10.
IL-2 substitution-defined variant embodiment
An IL-2 variant contains at least one amino-acid substitution selected from R38A, F42A, Y45A, E61R, or L72G in the sequence of SEQ ID NO: 10.
IL-2 variant sequence restriction by SEQ ID numbers
The IL-2 variant has the amino acid sequence of SEQ ID NO: 6, 22, 23, or 24.
Linker (1) as SEQ ID NO:3 peptide linker
The linker (1) is a peptide linker made from the amino acid sequence of SEQ ID NO: 3.
Cancer indication restriction for application to an individual
Applied to an individual with cancer, where the cancer is selected from a specified list of cancer types.
The claim set is anchored on a caged-cytokine composition using a photon-decomposing chemical structure with a 2-nitrobenzyl group, conjugated via a linking group to a hydrophilic polymer, with cytokine selection covering IL-2, IL-7, IL-12, and IL-15. Coverage is narrowed in dependent claims by specifying IL-2 embodiments using SEQ ID-defined sequences and defined substitution patterns, constraining linker features to a SEQ ID NO:3 peptide linker, and restricting the cancer treatment context to enumerated cancer types.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?